This inventor holds 1 USPTO granted patent. Top assignee: Fqubed Inc.. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Edward T Kisak: Innovator in Topical Formulation
Introduction
Edward T Kisak is an accomplished inventor based in La Jolla, California, with a significant contribution to the field of pharmaceuticals. His innovative work focuses on topical formulations that enhance the delivery of therapeutic agents through the skin.
Latest Patents
Edward T Kisak holds a patent for a topical formulation that includes diclofenac or a pharmaceutically acceptable salt thereof. The patented formulation comprises diclofenac, a first compound, and a second compound, with each compound selected from a group that includes N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. This formulation has been demonstrated to be an effective penetration enhancer, allowing for improved administration of diclofenac while reducing the concentration of skin irritants.
Career Highlights
Kisak's dedication to innovation is exemplified by his work at Fqubed Inc., where he continues to explore new avenues for improving pharmaceutical formulations. His single patented invention showcases his ability to blend science and practicality in creating effective medical solutions.
Collaborations
Throughout his career, Edward has collaborated with talented professionals such as John Michael Newsam and Dominic King-Smith. These collaborations have fostered an environment of creativity and shared knowledge, contributing to advancements in topical formulations.
Conclusion
Edward T Kisak stands out as a notable inventor in the field of pharmaceutical innovation, particularly with his work on topical formulations that improve drug delivery. His contributions not only emphasize the importance of enhancing therapeutic efficacy but also address patient comfort through reduced skin irritants.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile